Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID PRESCOTT TIETJEN

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1508838384
CMS profile
159288
Location
HUNTSVILLE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$630.15

34 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $627.66 33
Education $2.49 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID PRESCOTT TIETJEN

NPI 1508838384 · CMS profile ID 159288

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

HUNTSVILLE, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508838384?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID PRESCOTT TIETJEN, NPI 1508838384, CMS profile ID 159288. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508838384?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DAVID PRESCOTT TIETJEN, NPI 1508838384, CMS profile ID 159288. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508838384?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DAVID PRESCOTT TIETJEN, NPI 1508838384, CMS profile ID 159288, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–34 of 34 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1508838384?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

34 matching records · $630.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 34 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–34 of 34.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Vifor Pharma, Inc. $20.0512/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896733489 CMS
Aurinia Pharma U.S., Inc. $20.1112/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954105883 CMS
Vifor Pharma, Inc. $14.2711/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896733473 CMS
Vifor Pharma, Inc. $21.4910/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896733493 CMS
OPKO Pharmaceuticals, LLC $12.2210/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929039631 CMS
Alexion Pharmaceuticals, Inc. $18.7610/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914929809 CMS
Otsuka America Pharmaceutical, Inc. $19.3110/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929346209 CMS
Amgen Inc. $21.9610/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939934733 CMS
AstraZeneca Pharmaceuticals LP $16.8810/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915543067 CMS
Vifor Pharma, Inc. $15.0909/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896733477 CMS
OPKO Pharmaceuticals, LLC $16.7509/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929039627 CMS
Otsuka America Pharmaceutical, Inc. $12.3608/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929346207 CMS
Vifor Pharma, Inc. $19.0708/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896733485 CMS
GlaxoSmithKline, LLC. $16.0708/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945067251 CMS
Otsuka America Pharmaceutical, Inc. $14.6206/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929346205 CMS
Daiichi Sankyo Inc. $18.4206/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930843379 CMS
Amgen Inc. $20.6706/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939934727 CMS
Vifor Pharma, Inc. $23.9406/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896733497 CMS
Bayer HealthCare Pharmaceuticals Inc. $28.5506/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930080737 CMS
Otsuka America Pharmaceutical, Inc. $19.0805/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929346203 CMS
CALLIDITAS THERAPEUTICS US INC. $22.8205/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927062863 CMS
Bayer HealthCare Pharmaceuticals Inc. $26.6704/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930077565 CMS
Daiichi Sankyo Inc. $16.4704/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930822215 CMS
Amgen Inc. $15.7804/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939934731 CMS
Bayer HealthCare Pharmaceuticals Inc. $21.4704/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930000881 CMS
Otsuka America Pharmaceutical, Inc. $16.8304/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929346201 CMS
Travere Therapeutics, Inc. $2.4903/30/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960084123 CMS
Travere Therapeutics, Inc. $11.4503/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960084125 CMS
Amgen Inc. $13.3803/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939934729 CMS
CALLIDITAS THERAPEUTICS US INC. $24.9603/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927061329 CMS
Alexion Pharmaceuticals, Inc. $17.9102/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915676381 CMS
AKEBIA THERAPEUTICS INC $24.8501/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885306461 CMS
Vifor Pharma, Inc. $19.0201/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 896733481 CMS
Aurinia Pharma U.S., Inc. $26.3801/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954105881 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $462.83 30
PY2020 $279.61 18
PY2021 $646.77 24
PY2022 $630.15 34
PY2023 $655.62 29
PY2024 $538.52 20
PY2025 $311.01 12

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $86,493.87 37
PY2024 Principal investigator $77,411.65 31
PY2023 Principal investigator $244,765.38 77
PY2022 Principal investigator $437,199.28 132
PY2021 Principal investigator $475,627.60 160
PY2020 Principal investigator $841,410.33 80
PY2019 Principal investigator $476,990.58 451

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

80 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AKEBIA THERAPEUTICS INC $16,204.00 12/21/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753287203
Principal investigator 1 Boehringer Ingelheim International GmbH $4,570.00 12/18/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 753392137
Principal investigator 1 AKEBIA THERAPEUTICS INC $17,175.00 11/16/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OR MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH INCIDENT DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE - CORRECTION/CONVERSION) No dispute reported 06/30/2026 753286703
Principal investigator 1 Boehringer Ingelheim International GmbH $20,135.00 11/16/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 753392135
Principal investigator 1 Horizon Therapeutics plc $44,760.00 11/05/2020 Non-covered Recipient Entity
FRENOVA LLC
A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF PEGLOTICASE IN PATIENTS WITH UNCONTROLLED GOUT WHO HAVE UNDERGONE KIDNEY TRANSPLANTATION No dispute reported 06/30/2026 723128045
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $24,397.86 10/31/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 750753999
Principal investigator 1 AKEBIA THERAPEUTICS INC $30,000.00 10/21/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OR MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH INCIDENT DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE - CORRECTION/CONVERSION) No dispute reported 06/30/2026 753286579
Principal investigator 1 Boehringer Ingelheim International GmbH $12,265.00 10/15/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 753392133
Principal investigator 1 Boehringer Ingelheim International GmbH $10,160.00 09/18/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 749904957
Principal investigator 1 AKEBIA THERAPEUTICS INC $44,895.00 09/02/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753286261
Principal investigator 1 AKEBIA THERAPEUTICS INC $44,822.00 09/02/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753286269
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $24,397.86 08/31/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 750753977
Principal investigator 1 Boehringer Ingelheim International GmbH $4,630.00 08/19/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 749904955
Principal investigator 1 GlaxoSmithKline, LLC. $3,900.00 08/14/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734922119
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $50,617.95 07/27/2020 Non-covered Recipient Entity
Nephrology Consultants
MRD for BI 685509 in DN Patients No dispute reported 06/30/2026 751190827
Principal investigator 1 GlaxoSmithKline, LLC. $1,661.40 07/24/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734906141
Principal investigator 1 GlaxoSmithKline, LLC. $2,519.01 07/24/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734907341
Principal investigator 1 GlaxoSmithKline, LLC. $1,591.20 07/24/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734910025
Principal investigator 1 Boehringer Ingelheim International GmbH $8,225.00 07/15/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 749904953
Principal investigator 1 AKEBIA THERAPEUTICS INC $12,252.05 07/13/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753285673
Principal investigator 1 GlaxoSmithKline, LLC. $2,214.81 07/10/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734910583
Principal investigator 1 GlaxoSmithKline, LLC. $1,164.15 07/08/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734919991
Principal investigator 1 GlaxoSmithKline, LLC. $1,209.78 07/06/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734918921
Principal investigator 1 AKEBIA THERAPEUTICS INC $10,480.50 07/01/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753285109
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 06/23/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734915155
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 06/18/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734928711
Principal investigator 1 Boehringer Ingelheim International GmbH $23,420.00 06/15/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 749904963
Principal investigator 1 AKEBIA THERAPEUTICS INC $490.50 06/09/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753284539
Principal investigator 1 GlaxoSmithKline, LLC. $877.50 06/03/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734911465
Principal investigator 1 AKEBIA THERAPEUTICS INC $627.30 06/02/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753284257
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $12,198.93 05/31/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 750753975
Principal investigator 1 GlaxoSmithKline, LLC. $8,775.00 05/27/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734908215
Principal investigator 1 GlaxoSmithKline, LLC. $4,709.25 05/27/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734909323
Principal investigator 1 GlaxoSmithKline, LLC. $11,194.56 05/20/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734928465
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 05/19/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734922587
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 05/15/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734918877
Principal investigator 1 Boehringer Ingelheim International GmbH $25,115.00 05/13/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 749904951
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,355.30 05/07/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753283619
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,200.60 05/06/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753283569
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $24,397.86 04/30/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 750754001
Principal investigator 1 Boehringer Ingelheim International GmbH $29,940.00 04/20/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 749904949
Principal investigator 1 GlaxoSmithKline, LLC. $4,832.10 04/15/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734899567
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 04/02/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734904713
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,911.60 04/01/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753282805
Principal investigator 1 AKEBIA THERAPEUTICS INC $490.50 04/01/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753282855
Principal investigator 1 GlaxoSmithKline, LLC. $1,737.45 04/01/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734917109
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $24,397.86 03/31/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 750753969
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $24,397.86 03/31/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 750753971
Principal investigator 1 GlaxoSmithKline, LLC. $2,086.85 03/27/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734900903
Principal investigator 1 GlaxoSmithKline, LLC. $1,001.95 03/27/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734900905
Principal investigator 1 AKEBIA THERAPEUTICS INC $4,779.00 03/18/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753282277
Principal investigator 1 GlaxoSmithKline, LLC. $1,780.74 03/18/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734928257
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,823.20 03/17/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753282203
Principal investigator 1 Boehringer Ingelheim International GmbH $15,950.00 03/16/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 749904961
Principal investigator 1 GlaxoSmithKline, LLC. $3,886.74 03/13/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734902923
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 03/09/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734905251
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,400.00 03/04/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OR MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH INCIDENT DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE - CORRECTION/CONVERSION) No dispute reported 06/30/2026 753281923
Principal investigator 1 AKEBIA THERAPEUTICS INC $750.00 03/02/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OR MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH INCIDENT DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE - CORRECTION/CONVERSION) No dispute reported 06/30/2026 753281775
Principal investigator 1 GlaxoSmithKline, LLC. $16,917.03 03/02/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734905739
Principal investigator 1 GlaxoSmithKline, LLC. $150.00 03/01/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734907539
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $12,198.93 02/29/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 750753973
Principal investigator 1 AKEBIA THERAPEUTICS INC $6,465.60 02/25/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753289423
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,250.00 02/25/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753289537
Principal investigator 1 AKEBIA THERAPEUTICS INC $5,660.10 02/24/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753289261
Principal investigator 1 GlaxoSmithKline, LLC. $11,400.00 02/20/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734907537
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,500.00 02/18/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753289091
Principal investigator 1 Boehringer Ingelheim International GmbH $42,000.00 02/18/2020 Non-covered Recipient Entity
Nephrology Consultants
EMPA-KIDNEY No dispute reported 06/30/2026 749904959
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,093.50 02/14/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OR MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH INCIDENT DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE - CORRECTION/CONVERSION) No dispute reported 06/30/2026 753288981
Principal investigator 1 GlaxoSmithKline, LLC. $10,800.00 02/13/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734905249
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,722.60 02/12/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753288867
Principal investigator 1 GlaxoSmithKline, LLC. $9,450.00 02/07/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734907581
Principal investigator 1 AKEBIA THERAPEUTICS INC $5,067.00 02/06/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753288627
Principal investigator 1 GlaxoSmithKline, LLC. $12,600.00 02/05/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734899905
Principal investigator 1 GlaxoSmithKline, LLC. $12,600.00 02/05/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734913509
Principal investigator 1 AKEBIA THERAPEUTICS INC $5,252.40 02/03/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753288245
Principal investigator 1 GlaxoSmithKline, LLC. $23,700.00 02/01/2020 Non-covered Recipient Entity
FRESENIUS MANAGMENT SERVICES INC
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 734906665
Principal investigator 1 AKEBIA THERAPEUTICS INC $327.00 01/20/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OR MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH INCIDENT DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE - CORRECTION/CONVERSION) No dispute reported 06/30/2026 753287957
Principal investigator 1 AKEBIA THERAPEUTICS INC $12,186.75 01/10/2020 Non-covered Recipient Entity
FRENOVA LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (DD-CKD) (INNO2VATE-CONVERSION) No dispute reported 06/30/2026 753287871
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,485.80 01/02/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE CORRECTION OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CORRECTION) No dispute reported 06/30/2026 753287733
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,308.40 01/02/2020 Non-covered Recipient Entity
NEPHROLOGY CONSULTANTS LLC
PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE MAINTENANCE TREATMENT OF ANEMIA IN SUBJECTS WITH NON-DIALYSIS-DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) (PRO2TECT-CONVERSION) No dispute reported 06/30/2026 753289035